UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, I ...

Financial Data and Key Metrics Changes - Net sales for Q1 2020 were $571.6 million, a 3.2% increase from $554 million in Q1 2019, with a 4.3% increase on a currency neutral basis [15] - Reported gross margin for Q1 2020 was 55.5%, down from 56.3% in Q1 2019, primarily due to a prior year's escrow release [22] - Reported net income for Q1 2020 was $685.9 million, with diluted earnings per share of $22.72, a decrease attributed to the valuation of Sartorius Holdings [25] - Non-GAAP net income for Q1 2020 was $57.6 million, or $1.91 diluted earnings per share, compared to $49.6 million and $1.65 per share in Q1 2019 [29] Business Line Data and Key Metrics Changes - Life Science Group sales were $227.2 million, a 5.3% increase from $215.7 million in Q1 2019, driven by strong demand for PCR and Droplet Digital PCR products [17] - Clinical Diagnostics sales were $343 million, a 1.9% increase from $334.1 million in Q1 2019, with growth in blood typing and quality controls offset by declines in diabetes and immunology product lines [19][20] Market Data and Key Metrics Changes - Sales in all regions were impacted by COVID-19, with demand tapering in the U.S. and Europe late in the quarter [15] - Life Science sales grew in Asia and Europe on a currency neutral basis, with growth in the Americas when excluding Process Media [19] Company Strategy and Development Direction - The company is focused on maintaining employee safety, ensuring product supply continuity, and progressing on core strategies amid the pandemic [9][12] - The recent acquisition of Celsee for $100 million aims to enhance capabilities in single-cell analysis, indicating a strategic focus on expanding technological applications [31][55] Management's Comments on Operating Environment and Future Outlook - Management withdrew annual guidance due to uncertainties from COVID-19, expecting Q2 sales to decline by 10% to 15% but anticipating recovery in the second half of the year [33] - The company continues to monitor demand and supply indicators, emphasizing a disciplined approach to expenses and operational adjustments [45] Other Important Information - The company has implemented cost-saving initiatives, resulting in SG&A expenses decreasing to 33.9% of sales from 37.5% in Q1 2019 [23] - The adjusted EBITDA for Q1 2020 was $107.4 million, or 18.8% of sales, compared to $101.7 million, or 18.4% in Q1 2019 [32] Q&A Session Summary Question: What is Bio-Rad's strategy in the serology antibody test market? - Management highlighted the platform's open system as a key differentiator, suitable for medium-sized labs and complementary to high-throughput systems [36] Question: How does the company view the impact of COVID-19 on Q2 revenue? - Management indicated that the return to work and demand for core PCR instruments will be significant factors in Q2 revenue, with ongoing monitoring of elective surgeries and clinic visits [40][41] Question: What measures are being taken to maintain margins amid revenue pressure? - The company is closely monitoring demand versus supply and has implemented cost-saving measures, including reduced discretionary spending [44][45] Question: What is the expected growth for the blood typing business? - Management expects a return to normalcy in blood typing as elective surgeries resume, although the market is generally slow-growing [47] Question: Can you elaborate on the Celsee acquisition objectives? - The acquisition is aimed at enhancing capabilities in single-cell analysis, with a focus on expanding applications in transcriptomic and genomic studies [55]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2019 Earnings Conference Call February 13, 2020 5:00 PM ET Company Participants Ron Hutton - Vice President & Treasurer Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Annette Tumolo - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Dan Leonard - Wells Far ...

BIO RAD Bio-Rad Laboratories, Inc. J.P. Morgan 2020 Healthcare Conference Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our performance in high growth emerging markets, continuing innovation and new products and technologies, our new focus on lab to clinic solutions, continuing and emerging leadership positions in various markets, ...

[Part I – Financial Information](index=4&type=section&id=Part%20I%20%E2%80%93%20Financial%20Information) [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Financial statements reflect increased assets, a Q3 net loss from equity valuation, and stable nine-month net income with strong cash flow [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance sheet shows increased total assets from investments and new lease assets, with liabilities and equity also rising Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | September 30, 2019 (Unaudited) | December 31, 2018 | | :--- | :--- | :--- | | **Total current assets** | $2,047,632 | $2,023,478 | | **Operating lease right-of-use assets** | $217,516 | $— | | **Other investments** | $3,931,715 | $2,655,709 | | **Total assets** | **$7,177,116** | **$5,611,068** | | **Total current liabilities** | $434,040 | $450,795 | | **Operating lease liabilities** | $192,600 | $— | | **Total liabilities** | **$2,045,924** | **$1,590,737** | | **Total stockholders' equity** | **$5,131,192** | **$4,020,331** | - The adoption of new lease accounting standard ASC 842 in 2019 resulted in the recognition of **$217.5 million** in operating lease right-of-use assets and a corresponding **$226.3 million** in lease liabilities (**$33.7 million** current, **$192.6 million** non-current)[7](index=7&type=chunk)[8](index=8&type=chunk)[123](index=123&type=chunk) [Condensed Consolidated Statements of Income](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) Q3 2019 net sales increased but a large unrealized equity loss resulted in a net loss, while nine-month net income was strong from equity gains Key Income Statement Data (in thousands, except per share data) | Metric | Q3 2019 | Q3 2018 | 9 Months 2019 | 9 Months 2018 | | :--- | :--- | :--- | :--- | :--- | | **Net sales** | $560,633 | $545,138 | $1,687,231 | $1,672,568 | | **Gross profit** | $307,026 | $286,716 | $926,557 | $890,586 | | **Income from operations** | $57,460 | $36,275 | $170,456 | $123,713 | | **Change in fair market value of equity securities** | ($390,620) | $318,007 | $1,384,999 | $1,420,339 | | **Net (loss) income** | ($258,816) | $269,326 | $1,205,189 | $1,194,143 | | **Diluted (loss) earnings per share** | ($8.68) | $8.89 | $39.97 | $39.50 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash flow statements show net cash from operations significantly increased, with cash used for acquisitions and treasury stock repurchases Cash Flow Summary (in thousands) | Cash Flow Activity | Nine Months Ended Sep 30, 2019 | Nine Months Ended Sep 30, 2018 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $298,095 | $180,485 | | **Net cash used in investing activities** | ($147,693) | ($132,167) | | **Net cash used in financing activities** | ($17,975) | ($1,677) | | **Net increase in cash** | $129,188 | $50,606 | - The company used **$75.8 million** for acquisitions and **$20.0 million** for purchases of treasury stock during the first nine months of 2019[12](index=12&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail new accounting standards, acquisitions, equity investment impact, segment performance, a settled legal matter, and European restructuring - In August 2019, the company acquired a U.S. manufacturer for approximately **$60.0 million** for the Clinical Diagnostics segment, and in March 2019, it acquired a U.S. private company for approximately **$20.0 million** for the Life Science segment[54](index=54&type=chunk)[57](index=57&type=chunk) - The lawsuit filed by former general counsel Sanford S. Wadler was settled via a Confidential Settlement Agreement in September 2019, and the matter is now closed[110](index=110&type=chunk) - The company adopted lease accounting standard ASC 842 on January 1, 2019, resulting in the recognition of operating lease right-of-use assets of **$217.5 million** and total operating lease liabilities of **$226.3 million**[49](index=49&type=chunk)[123](index=123&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=37&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management's discussion highlights Q3 sales growth, improved gross margin, strong liquidity, increased operating cash flow, and strategic cash deployment [Results of Operations](index=38&type=section&id=Results%20of%20Operations) Results show Q3 2019 net sales growth across segments with improved gross margin, and similar trends for the nine-month period Q3 2019 vs Q3 2018 Sales Growth | Segment | Reported Growth | Currency-Neutral Growth | | :--- | :--- | :--- | | **Total Company** | 2.8% | 4.5% | | **Life Science** | 4.5% | 5.7% | | **Clinical Diagnostics** | 2.4% | 4.3% | - The Q3 2019 consolidated gross margin increased to **54.8%** from **52.6%** in Q3 2018, driven by favorable product mix in Life Sciences and lower inventory and logistics costs in Clinical Diagnostics[144](index=144&type=chunk) - For the first nine months of 2019, Life Science sales grew **3.5%** (**5.7%** currency-neutral), while Clinical Diagnostics sales decreased **0.6%** (but grew **2.7%** currency-neutral)[152](index=152&type=chunk)[153](index=153&type=chunk) [Liquidity and Capital Resources](index=42&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity remains strong with substantial cash and investments, increased operating cash flow, and cash used for acquisitions and share repurchases - As of September 30, 2019, the company had **$979.2 million** in cash, cash equivalents, and short-term investments, and approximately **$209.0 million** available for borrowing under various credit facilities[165](index=165&type=chunk)[166](index=166&type=chunk) - Net cash provided by operations increased to **$298.1 million** for the first nine months of 2019, compared to **$180.5 million** for the same period in 2018, primarily due to lower cash paid to suppliers and employees and lower income tax payments[169](index=169&type=chunk) - During the first nine months of 2019, the company used cash for investing activities including two acquisitions for a net cash payment of **$75.8 million** and capital expenditures of **$76.9 million**[171](index=171&type=chunk)[174](index=174&type=chunk)[177](index=177&type=chunk) - Financing activities in the first nine months of 2019 included the repurchase of **$20.0 million** of common stock[178](index=178&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) No material changes to market risk disclosures were reported during the period - There have been no material changes in market risk during the nine months ended September 30, 2019[184](index=184&type=chunk) [Controls and Procedures](index=44&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective, with no material changes to internal control over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of September 30, 2019[186](index=186&type=chunk) - No material changes to internal control over financial reporting were identified during the third quarter of 2019[188](index=188&type=chunk) [Part II – Other Information](index=45&type=section&id=Part%20II%20%E2%80%93%20Other%20Information) [Legal Proceedings](index=45&type=section&id=Item%201.%20Legal%20Proceedings) A lawsuit with a former general counsel was settled and closed, with other legal actions not expected to have a material adverse effect - The lawsuit with former general counsel Sanford S. Wadler was settled and is now closed, with no material impact on Q3 2019 results[110](index=110&type=chunk)[189](index=189&type=chunk) [Risk Factors](index=45&type=section&id=Item%201A.%20Risk%20Factors) The company faces risks from international operations, ERP system implementation, equity investment market value, and extensive government regulation - Significant international operations (**60%** of net sales) expose the company to risks from foreign currency fluctuations, complex regulations like the FCPA and GDPR, and geopolitical uncertainties such as Brexit[194](index=194&type=chunk) - The multi-year implementation of a new global enterprise resource planning (ERP) system has previously caused disruptions and poses an ongoing risk to operations[203](index=203&type=chunk) - Changes in the market value of the company's investment in Sartorius AG can materially impact the Consolidated Statements of Income, as evidenced by the **$390.6 million** loss recognized in Q3 2019[257](index=257&type=chunk) - The company is subject to substantial government regulation from the FDA and foreign agencies, with evolving requirements potentially increasing costs and delaying product marketing[223](index=223&type=chunk)[225](index=225&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=59&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company repurchased **$5.0 million** of common stock under its **$250 million** program, with **$181.1 million** remaining available Share Repurchases in Q3 2019 | Period | Total Shares Purchased | Average Price Paid per Share | Total Purchased as Part of Program | Approx. Value Remaining in Program (millions) | | :--- | :--- | :--- | :--- | :--- | | Jul 2019 | — | $— | — | $186.1 | | Aug 2019 | 14,745 Class A | $339.05 | 14,745 Class A | $181.1 | | Sep 2019 | — | $— | — | $181.1 | - The Board of Directors authorized a **$250.0 million** share repurchase program in November 2017, which has no expiration date[275](index=275&type=chunk) [Defaults Upon Senior Securities](index=60&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) None reported - None[278](index=278&type=chunk) [Mine Safety Disclosures](index=60&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Not applicable - Not applicable[279](index=279&type=chunk) [Other Information](index=60&type=section&id=Item%205.%20Other%20Information) None reported - None[279](index=279&type=chunk) [Exhibits](index=61&type=section&id=Item%206.%20Exhibits) Exhibits include CEO and CFO certifications and Inline XBRL data files - Exhibits filed include CEO and CFO certifications pursuant to Sarbanes-Oxley Sections 302 and 906, and Inline XBRL documents[281](index=281&type=chunk) [Signatures](index=62&type=section&id=Signatures) The report was signed on November 1, 2019, by the Chairman, President, CEO, and Executive Vice President and CFO - The Form 10-Q was signed on November 1, 2019, by CEO Norman Schwartz and CFO Ilan Daskal[283](index=283&type=chunk)

Bio Rad Laboratories, Inc. (NYSE:BIO) Q3 2019 Earnings Conference Call October 31, 2019 5:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Norman Schwartz - Chairman, CEO & President Andrew Last - EVP & COO Annette Tumolo - EVP & President, Life Science Group John Hertia - EVP & President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Jack Meehan - Barclays Bank Operator Ladies and gentlemen, thank you for standing by, and welcome t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, IN ...

Bio Rad Laboratories (NYSE:BIO) Q2 2019 Earnings Conference Call August 1, 2019 5:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Norman Schwartz - Chairman, CEO & President Andrew Last - EVP & COO Annette Tumolo - EVP & President of Life Science Group John Hertia - EVP & President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Goldman Sachs Group Mitchell Petersen - Barclays Bank Daniel Leonard - Deutsche Bank Brandon Couillard - Jefferies O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...